| Pipe line |
Indications / Type of DDS |
Development stage |
| PC-SOD |
- Indications：
- Idiopathic Interstitial pneumonia
(IIP)
- Type of DDS：
- Targeting
Now there no drugs effective in IIP. It is hoped that PC-SOD is launched.
|
Phase II clinical study has been completed.
Phase III Clinical study is now under preparations.
|
| PC-SOD |
- Indications：
- Ulcerative colitis (UC)
- Type of DDS：
- Targeting
Medicine with a new action mechanism is expected.
|
Phase II clinical study has been completed.
Phase III Clinical study is now under preparations.
|
| SRG |
- Indications：
- Anticancer drug-induced neutropenia
- Type of DDS：
- Slow-release
The burden of the patient is reduced as a result of decreased number of doses.
|
Basic research |
| AS-013 |
- Indications：
- Peripheral Arterial Disease
- Type of DDS：
- Targeting
AS-013 is 2nd generation formulation of PGE1 targeting chronic arterial occlusion.
|
Phase II clinical study has been completed.
Phase III Clinical study is now under preparations.
|
| Nano-PGE1 |
- Indications：
- Peripheral Arterial Disease
- Type of DDS：
- Targeting/Slow-release/Stealth
Nano-PGE1 is 3rd generation formulation of PGE1. By one dosage, the effect of Nano-PGE1 lasts for two weeks.
|
Basic research |
| NSAID |
- Indications：
- Inflammatory disease
New type of non-steroidal anti-inflammatory drug with few side effects.
|
Basic research |
| Nano-steroid |
- Indications：
- Rheumatoid arthritis Collagen disease
- Type of DDS：
- Targeting/Slow-release/Stealth
Enhanced anti-inflammatory efficacy and reduction of side effects (Collaborative research with Cipla Ltd., India)
|
Basic research |
| HAp-IFN |
- Indications：
- Hepatitis C
- Type of DDS：
- Slow-release
The burden of the patient is reduced as a result of decreased number of doses.
|
Basic research |
